Assessing the uptake, engagement, and safety of a self-management app, COPD.Pal®, for Chronic Obstructive Pulmonary Disease : a pilot study by Knox, L. et al.
This is a repository copy of Assessing the uptake, engagement, and safety of a self-
management app, COPD.Pal®, for Chronic Obstructive Pulmonary Disease : a pilot study.




Knox, L. orcid.org/0000-0003-2545-1046, Gemine, R., Rees, S. et al. (5 more authors) 
(2021) Assessing the uptake, engagement, and safety of a self-management app, 
COPD.Pal®, for Chronic Obstructive Pulmonary Disease : a pilot study. Health and 





This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Vol.:(0123456789) 
Health and Technology 
https://doi.org/10.1007/s12553-021-00534-w
ORIGINAL PAPER
Assessing the uptake, engagement, and safety of a self‑management 
app, COPD.Pal®, for Chronic Obstructive Pulmonary Disease: a pilot 
study
Liam Knox1  · Rachel Gemine2,3 · Sarah Rees2 · Sarah Bowen2 · Phil Groom4 · David Taylor4 · Ian Bond4 · Keir Lewis2,3
Received: 14 January 2021 / Accepted: 15 February 2021 
© The Author(s) 2021
Abstract
Chronic Obstructive Pulmonary Disease (COPD) is a widespread condition that accounts for 3 million deaths worldwide 
annually. Despite being extensive healthcare users, people with COPD (PwCOPD) only spend approximately 1% of their time 
with a healthcare professional. The rest of the time, they are encouraged to self-manage their condition. To encourage better 
self-management, Bond Digital Health have created a mobile phone app called COPD.Pal® that helps PwCOPD keep track 
of their condition. This pilot study aimed to assess the safety, engagement, and early efficacy of the app. 25 PwCOPD were 
recruited and given COPD.Pal® for 6-weeks. Healthcare usage, self-management knowledge, app engagement, dyspnoea, 
and health-related quality of life were measured at baseline and at 6-weeks. A feedback questionnaire was also collected 
at follow-up. T-tests investigated whether differences between the time points were evident in the data. No statistically 
significant differences were found between the time points for any of the variables measured. Average app engagement 
was 31.8 days with 84% using COPD.Pal® for 20 or more days during the 6-weeks. 89% of participants stated they would 
use the app regularly after the study, with 56% stating they’d use it long-term. This study determined that a digital, self-
management app would be engaged with and early results indicate that the safety is non-inferior to standard care. Although 
self-management knowledge remained unaffected by app use, this study provided useful insights regarding how to improve 
this aspect. This represents one of few studies which involve end-users at an early stage of intervention development, an 
important strength of the research.
Keywords Chronic Obstructive Pulmonary Disease · Self-management · Pilot study · Technology Enabled Care Services · 
Telehealth
1 Introduction
With 210 million people diagnosed and three million annual 
deaths, Chronic Obstructive Pulmonary Disease (COPD) is 
a global problem [1]. People with COPD (PwCOPD) have 
daily symptoms, including dyspnoea, sputum production 
and coughing, in addition to a poorer health status, 
reduced exercise capacity, and impairment in lung function 
[2–4]. Furthermore, anxiety and depression are common 
comorbidities [5, 6]. Symptoms can become worse (above 
the day-to-day variation) during an acute exacerbation, 
commonly caused by infection or pollution. Exacerbations 
of COPD are the second most common cause of emergency 
admission in the UK, being responsible for one in eight (130 
000) of the total, 1 million bed days, and a National Health 
Service (NHS) expenditure of over £500m in 2015 [2].
Despite PwCOPD being extensive users of the NHS 
[7, 8], approximately only 1% of their time is spent with 
healthcare professionals [9]. The rest of the time, PwCOPD 
are encouraged to self-manage their condition. Relevant 
self-management behaviours include regular exercise, 
taking medication, being aware of symptoms, and attending 
healthcare appointments [2]. Effective self-management 
interventions have been associated with reduced hospital 
admissions and an average cost-saving of £671.59 per person 
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[10, 11]. As a result, supporting self-management behaviours 
has been highlighted as crucial for the care of PwCOPD [12]. 
However, despite these positive results, it is still important 
to ensure that new interventions (especially technological 
ones) do not compromise safety and studies promoting new 
methods of working should always investigate this aspect as 
studies have done previously [13, 14].
Despite the positive association between self-management 
and health outcomes [15], these behaviours are seldom 
taught, and rarely followed over prolonged periods [16]. 
This is illustrated by examining pulmonary rehabilitation (a 
multidisciplinary disease management course for PwCOPD) 
attendance and adherence rates. The most recent UK national 
audit found that of those who are invited to pulmonary 
rehabilitation, only 69% attend the initial assessment and 
42% complete the course [17, 18]. Studies investigating why 
PwCOPD do not engage in self-management behaviours 
have found a range of factors, including low motivation and 
a lack of emphasis on behavioural change [16, 19].
To enable PwCOPD to have a greater awareness of 
symptom changes, a digital, self-management app called 
COPD.Pal® was developed in partnership with Bond 
Digital Health Ltd. (BDH; Cardiff, UK; https ://bondh ealth . 
co.uk/) using a person-centred approach [20, 21]. COPD.
Pal® enables PwCOPD to log symptoms, wellness, and 
medications, with an aim that through the storing of 
this data, self-management, illness understanding, and 
confidence can be improved. Initial qualitative analyses 
demonstrate that this app is usable and acceptable to 
PwCOPD (ANONYMOUS); however, further research 
is needed to quantitatively evaluate safety and user 
engagement. Therefore, this research study was conducted 
to answer the research question: ‘Is a self-management, 
mobile phone app safe and do PwCOPD engage?’. The 
study also collected self-management knowledge data to 
begin investigating early efficacy of the app.
2  Methods
This study was a quantitative, single-arm, clinical pilot study 
designed to evaluate the safety and user engagement of COPD.
Pal®. Participants completed baseline and six week, follow-up 
questionnaires using COPD.Pal® in between these time points. 
The study was approved by a Research Ethics Committee (19/
WA/0347) and local research and development governance and 
is registered online (ISRCTN: 14530045).
2.1  Participants
PwCOPD were recruited between  20th January and  11th Feb-
ruary 2020 from Hywel Dda University Health Board, Wales. 
To be eligible, prospective participants had to have a clinical 
diagnosis of COPD as defined by GOLD [3]; 40 years old or 
more, 10 pack years smoking history, and spirometry ratio of 0.7 
with less than 80% predicted. Those that had a cognitive, visual, 
or motor impairment that would prevent them using a smart 
phone, or were a current hospital inpatient, were not eligible.
A total of 71 PwCOPD were invited to participate with 25 
being recruited by giving written informed consent. Nineteen 
were male, the mean age was 64 (standard deviation [SD] = 
7.71), pack year smoking history was 37.9 (SD = 18.6), and 
FEV1 was 49% (SD = 19.3%).
2.2  The COPD.Pal® intervention
For this study, all participants were provided with a mobile 
smart phone with the COPD.Pal® app already installed. A 
member of the research team guided the participant through the 
set-up process and then answered any questions. Participants 
were asked to use COPD.Pal® for six weeks; however, no 
lifestyle restrictions were implemented and PwCOPD were 
invited to use the app as they would use others.
COPD.Pal® collects a range of data from questionnaires, 
asked at different frequencies. This includes the modified 
Medical Research Council Dyspnoea scale (mMRC) [22] 
and the COPD Assessment Test (CAT) [23], which measure 
dyspnoea and health-related quality of life (HRQoL), 
respectively.
2.3  Data collection
Engagement with COPD.Pal® was collected automatically 
via the app. Outside of the app, data was collected at 
baseline and a 6-week follow-up. This included COPD self-
management knowledge and confidence, as assessed by the 
Understanding COPD questionnaire (UCOPD) [24], number 
of exacerbations over the past three months, hospital and 
General Practitioner (GP) attendances (due to COPD), and 
use of steroids. Follow-up data collection asked participants 
to report the same measures but since they started using 
COPD.Pal®. Additionally, a feedback questionnaire, 
containing Likert and free-text boxes (see Supplementary 
file 1), measuring usability and acceptability was completed 
at follow-up.
2.4  Analysis
Related t-tests were used to investigate whether there were 
differences between baseline and follow-up for the variables 
of HRQoL, dyspnoea, healthcare usage (i.e. exacerbations, 
hospitalisations, etc.), and self-management knowledge. 
COPD.Pal® engagement was calculated from the app as 
number of days out of the maximum (i.e. 6 weeks or 42 
days). Percentage of positives scores were calculated from 
the Likert section of the feedback questionnaire. Common 
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themes were identified from the free-text section of the 
feedback questionnaire and summarised.
3  Results
Participant data was collected through research questionnaires 
and the COPD.Pal® app. The research questionnaires were 
collected at baseline and 6-weeks. COPD.Pal® data was 
collected automatically at set time points. Table 1 shows 
baseline and follow-up data for the participants.
On average, participants used the app for 31.8 (SD = 
10.9) days out of 42 days, with 84% using COPD.Pal® for 
20 or more times over the study period.
No participants had any adverse events whilst using 
COPD.Pal®. Although hospitalisations, GP appointments, 
and antibiotic- and steroid-use reduced during the study, 
these differences were not statistically significant (p = 0.83, 
95% confidence intervals [CI] = -0.02-0.26; p = 0.16, 95% 
CI = -0.07-0.39; p = 0.13, 95% CI = -0.11-0.75; p = 0.33, 
95% CI = -0.13-0.38, respectively). Similarly, there were 
no statistically significant differences in HRQoL (p = 0.26, 
95% CI = -3.63-1.02) or dyspnoea scores (p = 0.74, 95% CI 
= -0.65-0.47).
No statistically significant differences were detected 
between baseline and follow-up self-management knowledge 
and confidence scores, either for Knowledge of COPD (p = 
0.21, 95% CI = -8.0-1.82), Ability to manage symptoms (p 
= 0.22, 95% CI = -8.9-2.18), Knowledge of ways to access 
help and support (p = 0.76, 95% CI = -7.09-9.65), or overall 
(p = 0.29, 95% CI = -6.45-2.01).
The feedback questionnaire completed at the end of the 
6-week period found that 89% of participants stated that 
they would use the app regularly, 61% found it useful, 
and 56% would use it long-term. Six people, however, did 
report technical difficulties with the mobile phones that were 
supplied as part of this study and this may have negatively 
affected scores.
The main themes within the free-text boxes on the 
feedback questionnaire regarded the repetitive nature of the 
questions, where participants described the same items being 
asked each day regardless of previous scores. Additionally, 
no detailed feedback was provided based upon these scores 
that limited the extent to which participants could learn 
from the information they had inputted. Lastly, participants 
believed that the app should include questions which relate to 
the holistic nature of COPD, providing opportunity to input 
information on how they felt both physically and mentally.
4  Discussion
This study aimed to understand whether a digital, self-
management app was safe and if PwCOPD would use it, 
whilst also beginning to collect and analyse data regarding 
the efficacy of COPD.Pal®.
Participants experienced no adverse events during the 
study and several variables actually showed more beneficial 
states at follow-up, albeit not to a statistically significant 
degree. Although this study includes a relatively small 
sample size, the lack of differences between the two time 
points does begin to indicate that the use of COPD.Pal® 
is non-inferior to the safety that standard care provides. 
Self-management interventions have been associated with 
reduced hospitalisations [11] and future research could 
investigate whether self-management apps replicate similar 
findings, in addition to reductions in GP appointments 
and medication usage (as findings suggest here). Previous 
literature has found that per-person medication costs for 
PwCOPD were, on average, between £328 and £954 per 
annum [25, 26]. Therefore, given the high prevalence of 
COPD, if effective self-management can reduce unnecessary 
medication usage, apps like COPD.Pal® could be associated 
with significant cost-savings.
Over 80% of participants used the app regularly and 56% 
stated they would use the app long-term if they were given 
the opportunity. This was despite several technical issues 
with the mobile phone handsets that were provided as part 
of the study. These results indicate that PwCOPD would 
use a digital, self-management app; however, participants 
indicated they were dissatisfied with the feedback they 
were provided and the limited selection of questionnaires 
that were available to answer daily. This feedback provides 
useful suggestions that can be easily addressed at this 
stage of technology development and increase engagement 
further; highlighting the importance of including end-
users within early-development of these interventions [20], 
Table 1:  Participant descriptive statistics at baseline and follow-up. 
Values are given as mean and standard deviation (in parentheses) 
unless otherwise stated.
Baseline Follow-up
HRQoL 21.8 (8.11) 23.0 (9.69)
Dyspnoea 3.04 (1.20) 3.09 (1.33)
Healthcare usage (n)
Hospitalisations 3 0




Knowledge of COPD 76.8 (20.4) 79.9 (16.6)
Ability to manage symptoms 70.2 (20.4) 73.5 (20.0)
Knowledge of ways to access help 
and support
58.1 (24.6) 56.8 (26.6)
Overall 70.1 (19.3) 72.3 (17.3)
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which is unfortunately lacking in most chronic healthcare 
interventions. Moreover, at this stage, COPD.Pal® does not 
incorporate any major psychological theory to help foster 
engagement, because selecting an appropriate theory was 
delayed to enable the consideration of initial testing (i.e. 
this study and a previous one; [21]. Use of such theories 
has widely been reported to increase long-term adherence 
[20, 27, 28]; therefore, the relatively high initial engagement 
demonstrated in this study could be increased further in 
future iterations of the app.
The aim of COPD.Pal® is to foster improved self-
management and confidence through providing PwCOPD 
an accurate method of tracking daily symptom fluctuations. 
To begin to test the early efficacy of the app, the UCOPD 
questionnaire was used to measure self-management 
knowledge. No statistically significant differences were 
found between the time points and therefore, in its current 
iteration, COPD.Pal® does not increase self-management 
knowledge; however, 61% of participants did find the 
app useful. It is important to note that this study was not 
statistically powered to find significant differences in the 
UCOPD variable and baseline scores show relatively 
high levels of self-management knowledge (thus making 
it unlikely for possible differences to be found in small 
samples). One exception to the high levels found is the 
average score for ‘knowledge of ways to access help and 
support’. Previous research conducted by the authors 
(unpublished) has also identified a relatively low score 
in this sub-scale and future research should be conducted 
to investigate the prevalence, impact, and solutions to 
overcome this deleterious finding. Interestingly, supporting 
self-management was a topic for which participants 
provided feedback, indicating that they wished to receive 
more information regarding the scores they entered into 
the app. Thus, it is possible that by incorporating methods 
to provide users with tailored information regarding 
their condition, self-management knowledge could be 
increased in future iterations. Previous research conducted 
on COPD.Pal® has also suggested that by including this 
feedback function, perceived usefulness of the app could 
be increased and, through this, benefits for adherence [21]. 
The want for tailored feedback also does strengthen the 
findings of the qualitative analysis of COPD.Pal® [21], 
which described how participants’ suggestions could be 
explained through the use of self-determination theory, 
particularly the concept of autonomy [29]. Future studies 
should investigate whether self-determination theory 
constructs may be beneficial in predicting important 
healthcare and research outcomes.
The main strength of this study is that it has recruited end-
users at an early stage of app development and thus responds 
to recommendations provided to support the creation of 
digital interventions [20]. Although only including a small 
sample size, this study, alongside a previous qualitative 
one [21], has provided useful information to inform the 
development of COPD.Pal® and future research projects. 
A limitation of the study is that, although it included a 
questionnaire to measure self-management knowledge, 
it didn’t measure the actual number of self-management 
activities in which the participant engaged. This was 
primarily because of the large range of relevant activities 
involved in COPD self-management (e.g. regular exercise, 
taking medication, attending appointments) [2] made it 
impractical to include a questionnaire that measured all of 
them. Nevertheless, future research could overcome this 
limitation by asking participants for the number of self-
management activities they conduct.
In conclusion, although this study represents the early 
testing of a self-management app, the results indicate that 
COPD.Pal® is non-inferior to the safety that standard 
care provides. The app enables PwCOPD to track their 
symptoms and participants are willing to engage over 
the short-term, with the majority indicating this would 
be continued long-term. Although no statistically 
significant differences were detected within this study 
for self-management knowledge, participants provided 
useful suggestions for how this aspect could be improved 
in future versions of the app. This represents important 
information collected near the beginning of development 
and highlights the need for more interventions to 
incorporate end-users throughout early testing of 
healthcare interventions. After responding to feedback 
obtained from this study, further research should be 
conducted to investigate the effectiveness of COPD.Pal® 
to empower PwCOPD to self-manage their condition. Such 
research should be fully statistically powered and could 
incorporate mixed-methodology into one study, to fully 
explore the app’s ability to positively impact healthcare 
usage, self-management knowledge, and facilitate 
communication between those with the condition and 
healthcare professionals.
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